IOBT

IO Biotech, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website iobiotech.com
Employees(FY) 57
ISIN US4497781090

Performance

-11.52%

-33.82%

-43.79%

-40.54%

-56.35%

YTD

-16.27%

Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Advanced Technical Analysis

Technical Analysis of IOBT 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors, as the prevailing trend appea...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IOBT

Stock Rank

Recent News & Updates

2024-11-11 18:05
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-11-11 03:05
IO Biotech Announces Participation in Upcoming Investor Conferences(Globenewswire)
2024-11-06 21:00
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study(Globenewswire)
2024-10-03 21:00
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting(Globenewswire)
2024-09-13 14:30
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer(Globenewswire)
2024-09-01 18:53
IO Biotechs melanoma treatment trial to continue after IDMC review(Yahoo Finance)
2024-08-30 04:05
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma(Globenewswire)
2024-08-26 04:05
IO Biotech Announces Participation in Upcoming Investor Conferences(Globenewswire)
2024-08-12 19:05
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-07-25 04:05
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024(Globenewswire)
2024-07-03 22:01
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets(Investorplace)
2024-05-22 20:30
IO Biotech to Present at Jefferies Global Healthcare Conference(Globenewswire)
2024-05-14 01:54
IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024(Investorplace)
2024-05-13 19:55
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-04-24 04:30
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-04-14 20:30
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness(Globenewswire)
2024-04-09 00:00
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103(Globenewswire)
2024-04-04 20:30
IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer(Globenewswire)
2024-04-04 20:30
IO Biotech Appoints Faical Miyara, Ph.D., as Chief Business Officer(Globenewswire)
2024-03-07 01:01
IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials(Yahoo Finance)
2024-03-06 03:11
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting(Globenewswire)
2024-03-05 09:52
IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023(Investorplace)
2024-03-05 03:40
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results(Globenewswire)
2024-02-26 03:05
IO Biotech to Present at 44th Annual Cowen Health Care Conference(Globenewswire)
2023-12-20 19:30
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial(Globenewswire)
2023-11-12 19:12
IO Biotech Announces 2023 Third Quarter Results(Globenewswire)
2023-11-12 19:00
IO Biotech Appoints Helen Collins, MD, to its Board of Directors(Globenewswire)
2023-11-09 19:00
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma(Globenewswire)
2023-11-08 03:30
IO Biotech Announces Participation in Upcoming Investor Conferences(Globenewswire)
2023-10-31 20:30
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.